Journal of cannabis research最新文献

{"title":"Effect of screw pressing temperature on yield, bioactive compounds, and quality of hemp (Cannabis sativa L.) seed oil.","authors":"Aymane Allay, Abdessamad Ben Moumen, Youssef Rbah, Marie-Laure Fauconnier, Jacques Nkengurutse, Hana Serghini Caid, Ahmed Elamrani, Farid Mansouri","doi":"10.1186/s42238-025-00296-6","DOIUrl":"10.1186/s42238-025-00296-6","url":null,"abstract":"<p><strong>Background: </strong>Screw press extraction is widely used due to its simplicity and efficiency, but the impact of extraction temperature on oil characteristics requires further study. Existing studies highlight that high temperatures can improve yield but compromise oil quality. This study aims to assess the effects of different screw press extraction temperatures on hemp oil yield, composition and quality.</p><p><strong>Methods: </strong>The study was conducted to examine the influence of screw press extraction temperatures (30, 60, 80, 100, 120 and 140 °C) on hemp oil yield and quality. Extracted oils were analyzed according to key parameters, including oil yield, total phenolic content, tocopherols, oxidation stability index (OSI), pigments, quality indices (free fatty acids (FFA), peroxide value (PV), conjugated diene (K232) and conjugated triene (K270)), fatty acid profiles and color parameters (L*, a*, b*, C*_ab and h_ab). The differences between oils extracted by pressing at different temperatures were evaluated via one-way multivariate analysis of variance.</p><p><strong>Results: </strong>The temperature played a key role in yield, reaching a maximum of 21.82%, representing an oil recovery of 66.68% at 100 °C, an improvement of approximately 4% over cold pressing (30 °C). Increasing the extraction temperature from 30 °C to 140 °C resulted in an increase in tocopherol content from 410.84 mg/kg to 512.98 mg/kg. On the other hand, temperature had no significant effect on the TPC, which varied from 31.76 mg GAE/kg to 41.89 mg GAE/kg as confirmed by HPLC-DAD/ESI-MS² analysis. On the other hand, oils extracted at higher temperatures were lower in quality, with higher PV, ranging from 6.36 meq O₂/kg at 30 °C to 13.86 meq O₂/kg at 140 °C, accompanied by a slight decrease in OSI. In addition, a decrease in chlorophyll-a content was observed, from 54.60 mg/kg at 30 °C to 36.10 mg/kg at 140 °C, which also led to a reduction in the a* value (green hue). Despite these alterations, the fatty acid profiles remained constant, whatever the thermal regime applied.</p><p><strong>Conclusion: </strong>Extraction temperature has a significant influence on the yield and quality of hemp oil. Underline the importance of selecting the optimum extraction temperature to balance yield and quality.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"37"},"PeriodicalIF":4.1,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12175407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144328328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and psychosocial changes in adults with opioid use disorder and chronic pain using medical cannabis: a brief report.","authors":"Michelle R Lent, Ryan Keen, Michael Ruiz, Hannah R Callahan, Katherine E Galluzzi, Karen L Dugosh","doi":"10.1186/s42238-025-00297-5","DOIUrl":"10.1186/s42238-025-00297-5","url":null,"abstract":"<p><strong>Background: </strong>Medical cannabis (MC) is approved for the treatment of opioid use disorder (OUD) in Pennsylvania, but little is known about how MC impacts illicit opioid use or the clinical and psychosocial factors including pain severity levels that can precede illicit opioid use. This observational study examined the extent to which changes in rates of illicit opioid use and in pain and psychosocial functioning were observed following the first three months of MC treatment.</p><p><strong>Methods: </strong>A referred sample of 47 adults taking buprenorphine/naloxone for OUD with a minimum pain severity rating of 5/10 enrolled from March 2022-April 2023. Participants were recruited from an outpatient MC physician recommender's office and were offered a discounted MC 1:1 tetrahydrocannabinol:cannabidiol 5 mg:5 mg daily oral capsule. The primary study outcomes were pain severity, self-efficacy and interference, and the rates of illicit substance use as assessed via urine drug screening (UDS).</p><p><strong>Results: </strong>Participants (64% male, 49% Black, average age = 44 years) reported significant decreases in pain severity from baseline (M = 5.18, SD = 2.09) to Month 3 (M = 4.39, SD = 2.28), P < 0.01, Cohen's d = 0.54, and pain interference from baseline (M = 5.21, SD = 2.79) to Month 3 (M = 4.32, SD = 2.86), P < 0.01, Cohen's d = 0.47, and increases in pain-related self-efficacy from baseline (M = 6.55, SD = 3.57) to Month 3 (M = 8.05, SD = 3.30), P < 0.01, Cohen's d = 0.44. Rates of opioid use (X²[1] = 4.00, P = 0.13) did not differ significantly from baseline (16%) to Month 3 (5%). Cravings for opioids were mildly higher at baseline (M = 2.15, SD = 2.88) than at 3-months (M = 1.78, SD = 2.95) but this difference was not statistically significant, P = 0.49, d = 0.1. Sleep quality scores improved significantly from baseline (M = 12.38, SD = 4.40) to Month 3 (M = 10.95, SD = 4.95), P < 0.05, d = 0.33. Quality of life significantly improved in seven of eight domains (P < 0.05).</p><p><strong>Conclusion: </strong>MC treatment initiation was associated with reductions in pain severity and interference and improvements in quality of life and sleep quality, but not in illicit opioid use or cravings in adults with chronic pain receiving buprenorphine/naloxone for OUD.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"36"},"PeriodicalIF":4.1,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12175341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144328327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing cannabinoid bioavailability: a crossover study comparing a novel self-nanoemulsifying drug delivery system and a commercial oil-based formulation.","authors":"Vered Hermush, Nisim Mizrahi, Tal Brodezky, Rafael Ezra","doi":"10.1186/s42238-025-00294-8","DOIUrl":"10.1186/s42238-025-00294-8","url":null,"abstract":"<p><strong>Purpose: </strong>The oral bioavailability of cannabinoids is limited due to extensive first-pass metabolism, reducing their therapeutic efficacy. This study aimed to evaluate the pharmacokinetics and relative bioavailability of cannabinoids delivered via delta-9-tetrahydrocannabinol/cannabidiol self-emulsifying (THC/CBD-SE) powder, a self-nanoemulsifying drug delivery system, compared to standard oil-based drops.</p><p><strong>Methods: </strong>Fourteen healthy volunteers (3 men, 11 women) participated in a crossover study. Each received a single oral doses of 8 mg THC and 8 mg CBD in both formulations, with a 30-day washout period between treatments. Blood samples were collected at specified intervals post-administration to assess pharmacokinetic parameters, including maximum plasma concentration (Cmax) and time to reach Cmax (Tmax).</p><p><strong>Results: </strong>THC/CBD-SE Powder significantly enhanced Cmax for THC (32.79 ± 44.37 ng/mL) and its metabolite 11-OH-THC (10.91 ± 6.64 ng/mL) compared to oil-based drops (THC: 10.17 ± 11.41 ng/mL; 11-OH-THC: 4.64 ± 2.55 ng/mL). Similarly, Cmax for 7-OH-CBD was higher with THC/CBD-SE Powder (2.38 ± 1.63 ng/mL vs. 0.86 ± 0.56 ng/mL). Tmax for 11-OH-THC and 7-OH-CBD was shorter with THC/CBD-SE Powder (0.86 ± 0.36 h vs. 4.54 ± 3.44 h and 1.11 ± 0.59 h vs. 4.68 ± 3.38 h, respectively), indicating a faster onset of action. The THC/CBD-SE Powder exhibited over double the relative bioavailability of cannabinoids compared to oil drops, suggesting improved absorption and rapid onset. Both formulations were well tolerated with no serious adverse events.</p><p><strong>Conclusion: </strong>THC/CBD-SE Powder significantly improves cannabinoid bioavailability and absorption rates compared to oil-based drops, offering a promising oral delivery method for enhanced therapeutic potential.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"35"},"PeriodicalIF":4.1,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the adaptive role of cannabidivarinic acid (CBDVA) in aphid defense in Cannabis sativa.","authors":"Jacob MacWilliams, Venkatesh Padimi, Olivia Carter, Korey Brownstein, Zachary Stansell, Tyler Gordon, Punya Nachappa","doi":"10.1186/s42238-025-00291-x","DOIUrl":"10.1186/s42238-025-00291-x","url":null,"abstract":"<p><strong>Background: </strong>Cannabis sativa has unique secondary metabolites known as cannabinoids, which include tetrahydrocannabinol (THC) and cannabidiol (CBD) and more than 100 related secondary metabolites. There is increasing evidence that cannabinoids can affect insect fecundity and survival. In this study, we assessed the role of a minor cannabinoid, cannabidivarinic acid (CBDVA) on fecundity and survival of C. sativa-adapted specialist aphid, cannabis aphid (Phorodon cannabis) and non-adapted, generalist aphid, green peach aphid (Myzus persicae).</p><p><strong>Methods: </strong>We evaluated a panel of high and low-CBDVA hemp genotypes obtained from the USDA-ARS Hemp Germplasm Collection at the Plant Genetic Resources Unit for cannabis aphid resistance in greenhouse experiments. Trichome measurements were recorded for genotypes with the highest and lowest aphid counts. To confirm the role of CBDVA, we performed artificial feeding assays by supplementing CBDVA in aphid diets in the laboratory.</p><p><strong>Results: </strong>We found that cannabis populations were significantly higher (Mean ± SE: 221.57 ± 37.27) on a low-CBDVA genotype compared to a high-CBDVA genotype (12.58 ± 3.53) after 14 days of aphid infestation. The high-CBDVA genotype had significantly more trichomes than the low-CBDVA genotype. Supplementation of CBDVA in artificial diets decreased cannabis aphid fecundity from 109.56 ± 10.01 nymphs on diet control and 52.67 ± 7.79 nymphs on DMSO control to 18.71 ± 5.21 nymphs on 1 mM CBDVA + DMSO supplementation after 4 days. CBDVA + DMSO supplementation decreased green peach aphid fecundity from 72.36 ± 6.82 on diet control and 72.50 ± 3.97 on DMSO control to 11.60 ± 2.60 on 0.5 mM CBDVA after 3 days.</p><p><strong>Conclusions: </strong>Our results show that CBDVA has insecticidal activity against cannabis aphids and green peach aphids. CBDVA's potential as a pure essential oil may be an environmentally sustainable pest management option for organic production systems.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"34"},"PeriodicalIF":4.1,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12153158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144277283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revealing the therapeutic potential of synthetic cannabinoids: a systematic review of cannabinoid receptor binding dynamics and their implications for cancer therapy.","authors":"Sahar S Alghamdi, Hussah N Albahlal, Danah E Aloumi, Sarah Bin Saqyah, Arwa Alsubait, Jehan Alamre, Mohammed Alrashed, Nada Alsuhabeny, Afrah E Mohammed","doi":"10.1186/s42238-025-00289-5","DOIUrl":"10.1186/s42238-025-00289-5","url":null,"abstract":"<p><strong>Background: </strong>Cancer remains a major global health issue, prompting the need for innovative treatment approaches that extend beyond conventional methods such as chemotherapy and radiation. The endocannabinoid system (ECS), primarily the cannabinoid receptors CB1R and CB2R, presents a promising opportunity for cancer therapy by selectively targeting cell signaling pathways. This systematic review intends to explore the mode of action of synthetic cannabinoids as potential anticancer agents and their impact on tumor growth in various cancer cell lines.</p><p><strong>Methods: </strong>Of the 287 articles identified between January 1990 and July 2024, 27 studies met strict criteria focusing on their anticancer effects. Data extraction and quality assessment were conducted using GRADE criteria and the Cochrane Risk of Bias tool, ensuring robust evaluation of the studies' reliability.</p><p><strong>Results: </strong>Various pharmacological actions of synthetic cannabinoids function as agonists, antagonists, and inverse agonists at the CB1R and CB2R receptors. Key findings indicate that CB2R agonists significantly reduce cancer cell proliferation through diverse mechanisms, with selective CB2R agonists effectively inhibiting cancer cell growth and survival. Studies involving CB1R antagonists, particularly in conjunction with CB2R agonists, highlight their role in blocking CB1R to either validate or enhance the efficacy of CB2R agonists in mitigating tumor growth. Inverse agonists targeting CB2R have shown moderate success in inducing cancer cell death by disrupting survival pathways. Notably, synthetic cannabinoid agonists display significant potential in targeting CB1 and CB2 receptors to inhibit tumor proliferation and promote apoptosis across various cancer types.</p><p><strong>Conclusion: </strong>The systematic review concludes that CB2R agonists can effectively inhibit tumor growth while inducing apoptosis in various cancers. Although CB1R agonists show potential in modulating cancer pathways, there is a notable lack of research on CB1 inverse agonists, emphasizing the need for further investigation. Additionally, the study advocates for greater exploration of mixed receptor agonist and receptor mode of action to validate these promising therapeutic approaches.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"33"},"PeriodicalIF":4.1,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Cannabis use is not associated with altered levels of physical activity: evidence from the repeated cross‑sectional Belgian Health Interview Survey.","authors":"Brent Vernaillen, Brecht Devleesschauwer, Stijn Vansteelandt, Lydia Gisle, Sabine Drieskens, Elena Damian","doi":"10.1186/s42238-025-00290-y","DOIUrl":"10.1186/s42238-025-00290-y","url":null,"abstract":"","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"32"},"PeriodicalIF":4.1,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12131560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three-day delta-9-tetrahydrocannabinol (THC) exposure eliminates long-term depression in ventral tegmental area of young, but not adult mice.","authors":"Michael Von Gunten, Seth Hoffman, Addison Smartt, Jeffrey G Edwards","doi":"10.1186/s42238-025-00287-7","DOIUrl":"10.1186/s42238-025-00287-7","url":null,"abstract":"<p><p>Ventral tegmental area (VTA) dopamine signaling plays a key role in reward learning and drug dependence. VTA dopamine cell activity is regulated in part by local GABA interneurons, which participate in regulating reward prediction. Previously, our lab identified a cannabinoid type 1 receptor (CB1)-dependent form of excitatory long-term depression (LTD) in VTA GABA cells. LTD was eliminated in both young and adult mice after 7-10-day delta-9-tetrahydrocannabinol (THC) exposure. To build off these previous findings, we used mouse ex vivo brain slices to examine whether young mice undergo THC-induced alterations to VTA GABA cell plasticity after fewer exposures than their adult counterparts, as human adolescents have increased sensitivity to THC. Whole-cell electrophysiological recordings were performed on young (P14-P54) and adult (P66-P240) mice treated with THC or vehicle control for 3 days, after which we attempted to induce CB1-dependent LTD ex vivo. Plasticity was eliminated in young but not adult mice after 3 days of THC treatment. Because our previous work illustrated age-dependent alterations to mRNA transcripts after chronic THC-treatment, we also performed quantitative real-time PCR to assess any age dependent differences of 3-day THC exposure on mRNA levels in the VTA. Quantitative PCR revealed no THC-induced changes for young or adult mice but did show several differences between young and adult control mice. This age-dependent impact of THC on synaptic activity could reveal a physiological mechanism underlying increased sensitivity of adolescents to THC-induced alterations to plasticity.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"30"},"PeriodicalIF":4.1,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144192642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of cigarette and e-cigarette use with cannabis-related risk perceptions and intentions.","authors":"Ronja Kleine, Barbara Isensee, Frauke Nees, Reiner Hanewinkel","doi":"10.1186/s42238-025-00288-6","DOIUrl":"10.1186/s42238-025-00288-6","url":null,"abstract":"<p><strong>Background: </strong>This study examines the associations of current use of combustible cigarettes or e-cigarettes with perceived risk of cannabis use and intention to use cannabis within the next year.</p><p><strong>Methods: </strong>Data from 8,521 German adolescents were collected between autumn 2021 and spring 2022. Former but not current users of cannabis or (e-)cigarettes were excluded from analyses. Mean age was 14.0 years, and 50.6% of the sample were female. Current cannabis use was reported by 5.8%, current use of combustible and/or e-cigarettes by 17.0%. We conducted linear regression models predicting 1) risk perception by (e-)cigarette use, and 2) intention to use cannabis by (e-)cigarette use and risk perception, among never cannabis users.</p><p><strong>Results: </strong>Use of cannabis and (e-)cigarettes were strongly associated. Perceiving cannabis as less harmful was associated with a higher intention to use cannabis. Among never cannabis users, dual users of combustible and e-cigarettes perceived cannabis as least harmful and had the highest intention to use cannabis, followed by combustible cigarette-only users, and then e-cigarette-only users. Never combustible nor e-cigarette users perceived cannabis as most harmful and had the lowest intention to use cannabis.</p><p><strong>Conclusion: </strong>Perception of cannabis as harmful might be a protective factor for intentions to use cannabis among German adolescents. Prevention programs should consider that adolescent combustible and e-cigarette users are a high-risk group for initiation of cannabis use.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"31"},"PeriodicalIF":4.1,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144192641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The influence of genetics on the endocannabinoid system gene expression and relevance for targeting reproductive conditions.","authors":"Keisuke Tanaka, Akwasi A Amoako, Sally Mortlock, Peter A W Rogers, Sarah J Holdsworth-Carson, Jacqueline F Donoghue, Wan Tinn Teh, Grant W Montgomery, Brett McKinnon","doi":"10.1186/s42238-025-00275-x","DOIUrl":"10.1186/s42238-025-00275-x","url":null,"abstract":"<p><strong>Background: </strong>Endocannabinoids are small lipid molecules that have critical roles in cellular proliferation and function. They are produced locally with their concentrations controlled via the endocannabinoid system (ECS). The important cellular functions of endocannabinoids have made them and the proteins that modulate their expression targets of potential interest for treatment in many different diseases including gynaecological conditions. There is significant evidence of heredity differences in the response to both exogenous and endogenous cannabinoids that hampers the identification of effective targets. Whether compounds targeting endocannabinoids will be effective therefore may rely on personal differences mediated through genetic architecture. To investigate the source of individual differences, we investigated the effects of genetic variants on the expression of the endocannabinoid system genes at both a systemic and individual tissue level with a particular focus on the female reproductive system and the endometrium.</p><p><strong>Methods: </strong>We performed this analysis using publicly available datasets, including the 31,684 participants from the eQTLGen database and 838 donors to the GTEx database which includes 49 different sources of tissue, as well as an in-house database of 206 endometrial samples. Analysis of the eQTLGen data identified 22,020 eQTLs that influenced 43 of the selected 70 ECS genes.</p><p><strong>Results: </strong>A comparison across 49 different tissues that included at least 70 different individuals in the GTEx dataset identified eQTL for 69 of the 70 different genes, confirming a tissue-specific influence. Comparisons among 11 different physiological system indicated that the female reproductive system was associated with a fewer number of eQTLs. Finally, in the endometrium, we detected Bonferroni significant genetic effects on one individual gene fatty acid binding protein 3 (FABP3), an intracellular transporter that delivers endocannabinoids to the enzyme responsible for its inactivation, with a further 14 independent FDR significant eQTL for 13 ECS genes.</p><p><strong>Conclusions: </strong>This is the first study to investigate the effects of genetic variants on the ECS gene transcription and indicates genetic variants have significant influence that are unique to each tissue. Our results highlight the effect of individual variation and the impact endocannabinoid based therapies may have on different tissue and physiological systems.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"29"},"PeriodicalIF":4.1,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12124005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144183599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mode matters: exploring how modes of cannabis administration affect THC plasma concentrations and subjective effects.","authors":"Margy Y Chen, Ashley Brooks-Russell, Angela D Bryan, L Cinnamon Bidwell","doi":"10.1186/s42238-025-00282-y","DOIUrl":"10.1186/s42238-025-00282-y","url":null,"abstract":"<p><p>As cannabis products become increasingly accessible and novel modes of administration like dabbing and vaping gain popularity, understanding how these modes impact use experiences and abuse liability is crucial. Existing studies primarily utilized laboratory settings with lower-potency research-grade cannabis, failing to capture common modes among individuals who use higher-potency legal market products. This study investigated how modes of administration impact plasma tetrahydrocannabinol (THC) concentrations and subjective effects using naturalistic administration of legal market products. We conducted a secondary analysis of two quasi-experimental studies involving 252 participants (46.4% female). Participants completed a baseline assessment where they reported demographics, substance use, and medical history and an experimental assessment where they administered their products via their preferred modes. These modes were categorized into four general modes of use: dabbing, vaping, bong-like, and joint-like. Primary outcomes included plasma THC concentrations and subjective drug effects, both of which varied significantly across modes. Compared with modes typically associated with flower products (i.e., bong-, joint-like modes), dabbing was associated with higher plasma THC concentrations and subjective effects, indicating greater THC exposure when using this mode and its associated products. Interestingly, dabbing and vaping exhibited more rapid reductions in levels of subjective intoxication over time, suggesting that higher levels of intoxication may not be sustained for these modes. This study underscores the significant impact of modes of administration on THC exposure and subjective drug effects among individuals who regularly use legal market cannabis. Results demonstrate the need for future research to better characterize and account for modes of administration and their associated products.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":"7 1","pages":"28"},"PeriodicalIF":4.1,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144133405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}